X4 PHARMACEUTICALS, INC Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2021-06-30 was $116.00K, a 52.63% increase year-over-year.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2020-06-30 was $76.00K.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for fiscal 2024 was $297.00K, a 9.19% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for fiscal 2023 was $272.00K, a 33.99% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for fiscal 2022 was $203.00K, a 7.31% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC stock issued during period, value, employee stock purchase plan for fiscal 2021 was $219.00K, a 29.59% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2024-12-31 | $297.00K 10-K · filed 2025-03-26 | |
| 2023-12-31 | $272.00K 10-K · filed 2025-03-26 | |
| 2022-12-31 | $203.00K 10-K · filed 2025-03-26 | |
| 2021-12-31 | $219.00K 10-K · filed 2024-03-21 | |
| 2021-06-30 | $116.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $169.00K 10-K · filed 2023-03-21 | |
| 2020-06-30 | $76.00K 10-Q · filed 2021-11-04 | |
| 2018-12-31 | $3.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |